Abstract
The aim of this study was to examine the protective action of (±)-(E)-ethyl-2-[(E)-hydroxyimino-5-nitro-3-hexenamide (FK409), a novel spontaneous nitric oxide releaser, on gastric lesions in experimental rats in comparison with cimetidine, the most popular histamine H2 antagonist. Both FK409 and cimetidine, administered orally, inhibited gastric lesion, induced by water immersion stress, dose-dependently, and their inhibitions were significant at 3.2 and 32 mg kg−1 respectively. However, only FK409 (32 mg kg−1, p.o.) significantly inhibited gastric lesion induced by acidified aspirin (76%). Cimetidine (up to 100 mg kg−1, p.o.) showed only 36% inhibition. FK409 has more potent anti-ulcer activity than cimetidine and in particular shows superior gastric cytoprotection in acidified aspirin-induced lesions. Thus, FK409 could become a beneficial orally active anti-ulcer drug for clinical use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
